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Poster Session-I 7358 consecutive children with high-risk lymphomas and solid tu-
mor malignancies were treated with cyclophosphamide and tar-
geted topotecan followed by autologous HSCT as consolidation
therapy in a phase I/II IRB-approved study between November
1998 and January 2004 at St. Jude. 21 participants (pts) were en-
rolled in the phase I portion of the study. 14 pts were enrolled in
phase I, level 1 consisting of topotecan 3mg/m2/day with subse-
quent doses targeted to total systemic exposure of 100 6 20 ng-
hr/ml (days -11 to -2) and cyclophosphamide 750mg/m2/day on
days -6 through -2 (total, 3.75g/m2). Topotecan concentrations
were measured on days -11 and -6 to determine subsequent dosage
adjustments. Cyclophosphamide dose escalation to 1g/m2/day (to-
tal, 5g/m2) on level 2 was excessively toxic, as 7 of 7 pts experienced
$ grade 3 regimen-related toxicity; 1 pt died of veno-occlusive dis-
ease. The next 37 pts were enrolled in phase II at level 1 as maxi-
mum tolerated dose was reached; further results will be on the 51
pts who received cyclophosphamide and topotecan at dose level 1.
Pts included neuroblastoma (26), sarcoma (8), lymphoma (8), brain
tumor (5), Wilms tumor (3), and retinoblastoma (1). Disease status
at enrollment included 11 (21.6%) CR1, 10 (19.7%) $CR2, 9
(17.6%) very good partial response, 7 (13.7%) partial response, 2
(3.9%) progressive disease, 10 (19.6%) stable disease, and 2
(3.9%) relapse disease. Median age at HSCT was 4.9 years (y)
(range, 1.5–21.3 y) and 52.9% were males. Of the 51 pts, 19 re-
ceived unmanipulated peripheral blood stem cell grafts and 32 mar-
row grafts. Most common grade 3 or 4 toxicities were hepatic,
gastrointestinal and skin. Pts achieved neutrophil and platelet en-
graftment at a median of 13 days (range, 8–33 days) and 24 days
(range, 8–91 days), respectively. Overall the median time to neutro-
phil engraftment for pts receiving marrow grafts was 18 days
(range, 10–33 days) and PBSC grafts 10 days (range, 8–12 days)
(p\ 0.0001). 25 (49%) remain alive at a median of 6.4 y (range,
4–9.8 y). 3- and 5-year OS and EFS for all and most common di-
agnoses are described in Table 1; none were statistically significant.
Cyclophosphamide 3.75g/m2 and targeted topotecan followed by
autologous HSCT produces acceptable toxicity and ability to
achieve long-term survival in children with high-risk lymphoma
and solid tumor malignancies; hepatic toxicity was dose-limiting
in the initial phase of the study.
The 3-year and 5-year OS and EFS for the 3 most common
diagnoses and all participants treated on this therapeutic
protocol.
3-year OS 3-year EFS 5-year OS 5-year EFSNeuroblastoma 73.1% 1/- 8.5% 42.3% 1/- 9.3% 57.7% 1/- 10.8% 38.5% 1/- 11.4%Lymphoma 75% 1/- 14.2% 50% 1/- 15.8% 75% 1/- 14.2% 50% 1/- 15.8%Sarcoma 50% 1/- 15.8% 37.5% 1/- 14.8% 50% 1/- 17.7% 37.5% 1/- 17.1%Total 64.7% 1/- 6.6% 41.2% 1/- 6.7% 56.7% 1/- 7.8% 39.2% 1/- 8.2%OS, overall survival; EFS, event-free survival198
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Steroid and immunosuppressant sparing treatments of cutaneous
chronic graft versus host disease (GVHD) in children are a desirable
strategy, due to serious side-effects especially on growing and devel-
oping children. Photo(chemo)therapy (PT) has been shown to exert
local immunomodulatory activity in a variety of diseases including
GVHD. Therefore, we investigated the effect of total 31 cycles of
PT (narrowband UVB, UVA-1, PUVA) in 28 pediatric patients
(pat.)with cutaneous cGVHD (10 lichenoid, 18 sclerodermoid). 25/
28 pat. (89%) presented with extensive GVHD and have been either
resistant to immunosuppressive therapy or showed contraindications
against standard immunosuppression. Underlying diseases for allo-
geneic stem cell transplantation were malignant and non malignant
diseases (18 and10, respectively) with a median follow up of 8,7 years(2.7–17.7). Stem cell source were bone marrow in 20/28 and periph-
eral blood in 8/28 pat. given after myeloablativ conditioning in 18 and
after reduced intensity conditioning in 10 pat. Topical therapy in all
pat. comprised corticosteroids and, in recent years pimecrolimus.
Treatment outcome after 10 UVA-1, 8 narrowband UVB, 7 oral
PUVA and 6 topical PUVA courses was evaluated retrospectively.1
pat. got narrowband-UVB monotherapy, 5 pat. received one and
21 pat. two and more systemic immunosuppressants in addition to
PT. PT was well tolerated by all pat. Improvement of skin lesions
was observed in all but one (96%) pat. Complete remission (CR)
was achieved in 7/31 (22%)courses, a very good partial response
(VGPR) that allowed tapering of immunosuppressive therapy and re-
sulted in CR in another 8 (25%). 8 courses (25%) induced a partial re-
sponse (PR) with subsequent tapering of immunosuppressants and
stable disease, 3 courses (9,6%) also led to PR but were followed by
relapse. 1 course was without effect (NR). One pat. did not respond
initially to narrowband UVB but completely cleared after being
switched to UVA-1 treatment.We conclude that PT is a feasible,
nonaggressive treatment that may be beneficial for pediatric patients
with cutaneous GVHD by reducing prolonged systemic immunosup-
pressive therapy. Further controlled prospective studies are required
to prove our expectations especially in UVA-1 as add on treatment for
sclerodermoid, extensive cutaneous GVHD in children.199
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Background: Pericardial effusion (PCE) has only sporadically
been reported in transplant recipients. We studied a large series of
pediatric patients undergoing unrelated umbilical cord blood trans-
plantation (UCBT) at a single center to investigate PCE comprehen-
sively.
Methods: Between 01/2000 and 05/2008, 423 consecutive pa-
tients (median age 4.3 years; range 0.1–20.2 years) undergoing
UCBT from a single cord blood unit (CBU) after myeloablative con-
ditioning regimen were studied (median follow-up 1.8 years; range,
0.5–8.7 years). By low resolution HLA-A and –B and high resolution
–DRB1 matching the CBU were 4/6 (53.8%), 5/6 (35.3%), or 6/6
(8.5%) matched. The patients (63% male; 33% CMV seropositive)
had malignant (53.2%; n5 225; leukemia, lymphoma, MDS, others)
and non-malignant (46.8%; n5 198; metabolic, immunodeficiency,
marrow failure; and hemoglobinopathies) diagnoses. Cytoreduction
contained TBI for 38.3% and cyclophosphamide for 69.5%
patients. The graft-vs.-host disease (GVHD) prophylaxis was
cyclosporine1cellcept in 25.8% (n 5 109) and cyclospori-
ne1methylprednisone in 73% (n 5 309) patients.
Results: A total of 108 (26%) patients developed at least one ep-
isode of PCE a median of 96 days (range, 9 – 2730 days) after trans-
plant. PCE severity was moderate to very large in 56 and very small
to moderate in 52 patients. Cardiac tamponade was seen in 28
(6.7%); pericardiocentesis was performed in 31 (7.3%); and 10
(2.4%) patients required pericardial window. Pericardial fluid did
not reveal infection by cytology, cultures, PCR, or other tests. Cu-
mulative incidence of PCE in patients with grades II-IV acute
GVHD was 35% compared to 22% in those with either grade I or
no evidence of acute GVHD. TBI, patient CMV serostatus, HLA
match, chronic GVHD, age or sex of the patient had no impact on
the incidence of PCE. PCE with tamponade was significantly higher
(p 5 0.02) and pericardiocentesis was needed more often (p 5 0.03)
in the patients on cellcept prophylaxis. The 1-yr post-UCBT
survival in patients developing PCE was 55% compared to 63% in
those without PCE. Twenty-eight (6.7%) patients with PCE had
concomitant pleural and/or peritoneal fluid collection consistent
with a ‘‘polyserositis syndrome’’.
Conclusion: Pericardial effusion occurs in a quarter of UCBT
recipients but only a few are clinically important. Large PCE
